{"protocolSection": {"identificationModule": {"nctId": "NCT02283814", "orgStudyIdInfo": {"id": "BIA-2093-120"}, "organization": {"fullName": "Bial - Portela C S.A.", "class": "INDUSTRY"}, "briefTitle": "A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate", "officialTitle": "A Phase-1, Open-label, Drug Interaction Study Between Eslicarbazepine Acetate 1200 mg and Topiramate 200 mg Following Multiple Dose Administrations in Healthy Male"}, "statusModule": {"statusVerifiedDate": "2014-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2007-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-11-03", "studyFirstSubmitQcDate": "2014-11-04", "studyFirstPostDateStruct": {"date": "2014-11-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-11-28", "resultsFirstSubmitQcDate": "2014-12-19", "resultsFirstPostDateStruct": {"date": "2014-12-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-12-19", "lastUpdatePostDateStruct": {"date": "2014-12-22", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bial - Portela C S.A.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers", "detailedDescription": "Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers: Group A: Pre-treatment with ESL, treatment with ESL and ascending doses of Topamax (TPM) in last phases; Group B: Pre-treatment with TPM, treatment with TPM and ascending doses of ESL in last phases"}, "conditionsModule": {"conditions": ["Epilepsy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 32, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group A BIA 2-093 + Topamax", "type": "EXPERIMENTAL", "description": "Group A\n\n* Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;\n* Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days\n* Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days", "interventionNames": ["Drug: BIA 2-093", "Drug: Topamax"]}, {"label": "Group B BIA 2-093 + Topamax", "type": "EXPERIMENTAL", "description": "* Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;\n* Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;\n* Treatment: 200 mg once daily dose of TPM administered for four consecutive days;\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days", "interventionNames": ["Drug: BIA 2-093", "Drug: Topamax"]}], "interventions": [{"type": "DRUG", "name": "BIA 2-093", "armGroupLabels": ["Group A BIA 2-093 + Topamax", "Group B BIA 2-093 + Topamax"], "otherNames": ["ESL, Eslicarbazepine acetate"]}, {"type": "DRUG", "name": "Topamax", "armGroupLabels": ["Group A BIA 2-093 + Topamax", "Group B BIA 2-093 + Topamax"], "otherNames": ["TPM"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cmax - the Maximum Plasma Concentration", "description": "BIA 2-194 and BIA 2-195 are metabolites/active forms of eslicarbazepine acetate", "timeFrame": "Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h"}, {"measure": "Tmax - the Time of Occurrence of Cmax", "description": "BIA 2-194 and BIA 2-195 are metabolites/active forms of eslicarbazepine acetate Both Groups A and B described in participant flow recieved BIA 2-093 and Topiramate. The results presented here are related with the different interventions in both groups", "timeFrame": "Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h"}], "secondaryOutcomes": [{"measure": "AUC\u03c4 - Cumulative Area Under the Plasma Concentration Time Curve Over the Dosing Interval at Steady State.", "timeFrame": "Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer\n* Male aged of at least 18 years but not older than 45 years with a body mass \u00edndex (BMI) greater than or equal to 19 and below 30 kg/m\n* Clinical laboratory values within the laboratory's stated normal range; i f not within this range, they must be without any clinical significance (laboratory tests are presented in section 6.1.1.3)\n* Healthy according to the medical history, laboratory results and physical\n* Light-, non- or ex-smokers. A light smoker is defined as someone smoking 1 0 cigarettes or less per day, and an ex-smoker i s defined as someone who completely stopped smoking for at least 1 2 months before day 1 of this study\n\nExclusion Criteria:\n\n* Significant history of hypersensitivity to topiramate, eslicarbazepine, oxcarbazepine, carbamazepine or any related products (including excipients of the formulations) as wel l as severe hypersensitivity reactions (like angioedema) to any drugs\n* Presence of significant gastrointestinal, l iver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects\n* History of significant gastrointestinal, liver o r kidney disease, o r surgery that may affect drug bioavailability, including but not limited to cholecystectomy\n* Presence of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic d isease\n* Presence o f significant heart disease o r disorder according to ECG\n* Presence or history of significant central nervous system disorder l ike convulsion or depression\n* Presence o r history o f significant ocular disease\n* Presence or history of severe hepatic impairment\n* Presence or history of renal insufficiency (serum creatinine level greater than 135 \u03bcmol/L)\n* History or presence of acidosis\n* Use of valproic acid in the previous 7 days prior to Day 1 of the study.\n* Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (\\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)\n* Any clinically significant illness in the previous 28 days before day 1 of this study\n* Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampin), in the previous 28 days before Day 1 of this study\n* Participation in another clinical trial or donation of 50 mL or more of blood in the previous 28 days before day 1 of this study\n* Donation of 500 mL or more of blood (Canadian B lood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study\n* Positive urine screening of drugs of abuse (drugs listing is presented in section 6.1.1.4).\n* Positive results to HIV, HBsAg or anti-HCV tests", "healthyVolunteers": true, "sex": "MALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Group A BIA 2-093 + Topamax", "description": "Group A\n\n* Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;\n* Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days\n* Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days\n\nBIA 2-093\n\nTopamax"}, {"id": "FG001", "title": "Group B BIA 2-093 + Topamax", "description": "* Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;\n* Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;\n* Treatment: 200 mg once daily dose of TPM administered for four consecutive days;\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days\n\nBIA 2-093\n\nTopamax"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Group A BIA 2-093 + Topamax", "description": "Group A\n\n* Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;\n* Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days\n* Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days\n\nBIA 2-093\n\nTopamax"}, {"id": "BG001", "title": "Group B BIA 2-093 + Topamax", "description": "* Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;\n* Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;\n* Treatment: 200 mg once daily dose of TPM administered for four consecutive days;\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days\n\nBIA 2-093\n\nTopamax"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "27"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "27"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "27"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Cmax - the Maximum Plasma Concentration", "description": "BIA 2-194 and BIA 2-195 are metabolites/active forms of eslicarbazepine acetate", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h", "groups": [{"id": "OG000", "title": "BIA 2-093 + TPM", "description": "BIA 2-093 - ESL; Eslicarbazepine acetate TPM - Topamax"}, {"id": "OG001", "title": "BIA 2-093", "description": "BIA 2-093 - ESL; Eslicarbazepine acetate"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Cmax (BIA 2-194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "21960.6", "spread": "2482"}, {"groupId": "OG001", "value": "25414.8", "spread": "3736"}]}]}, {"title": "Cmax (BIA 2-195)", "categories": [{"measurements": [{"groupId": "OG000", "value": "931.8", "spread": "216"}, {"groupId": "OG001", "value": "1062.6", "spread": "235"}]}]}]}, {"type": "PRIMARY", "title": "Tmax - the Time of Occurrence of Cmax", "description": "BIA 2-194 and BIA 2-195 are metabolites/active forms of eslicarbazepine acetate Both Groups A and B described in participant flow recieved BIA 2-093 and Topiramate. The results presented here are related with the different interventions in both groups", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h", "groups": [{"id": "OG000", "title": "BIA 2-093 + TPM", "description": "BIA 2-093 - ESL; Eslicarbazepine acetate TPM - Topamax"}, {"id": "OG001", "title": "BIA 2-093", "description": "BIA 2-093 - ESL; Eslicarbazepine acetate"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Tmax (BIA 2-194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.00", "spread": "0.96"}, {"groupId": "OG001", "value": "2.00", "spread": "0.97"}]}]}, {"title": "Tmax (BIA 2-195)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.00", "spread": "4.20"}, {"groupId": "OG001", "value": "6.00", "spread": "3.91"}]}]}]}, {"type": "SECONDARY", "title": "AUC\u03c4 - Cumulative Area Under the Plasma Concentration Time Curve Over the Dosing Interval at Steady State.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng.h/mL", "timeFrame": "Time Frame: Group A:Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration; Group B: Day 8 and 27 within 5 minutes prior dosing and 0.25,0.5,0.75,1,1.33,1.67,2,2.5,3,4,6,9,12,16 and 24h", "groups": [{"id": "OG000", "title": "BIA 2-093 + TPM", "description": "BIA 2-093 - ESL; Eslicarbazepine acetate TPM - Topamax"}, {"id": "OG001", "title": "BIA 2-093", "description": "BIA 2-093 - ESL; Eslicarbazepine acetate"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "AUC\u03c4 (BIA 2-194)", "categories": [{"measurements": [{"groupId": "OG000", "value": "361733.9", "spread": "38706"}, {"groupId": "OG001", "value": "389794.3", "spread": "35861"}]}]}, {"title": "AUC\u03c4 (BIA 2-195)", "categories": [{"measurements": [{"groupId": "OG000", "value": "19611.8", "spread": "4707"}, {"groupId": "OG001", "value": "22886.8", "spread": "5195"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Group A BIA 2-093 + Topamax", "description": "Group A\n\n* Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;\n* Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days\n* Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days\n\nBIA 2-093\n\nTopamax", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 15, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Group B BIA 2-093 + Topamax", "description": "* Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;\n* Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;\n* Treatment: 200 mg once daily dose of TPM administered for four consecutive days;\n* Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days\n* Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days\n\nBIA 2-093\n\nTopamax", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 13, "otherNumAtRisk": 16}], "otherEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Ocular hyperaemia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 16}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Diarrheoa", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}]}, {"term": "hypoaesthesia teeth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Lip dry", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 16}]}, {"term": "Reflux gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Tongue coated", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 16}]}, {"term": "Feeling drunk", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Feeling hot", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "hot flush", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Venipuncture site redness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Vessel puncture site bruise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Red blood cells urine positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Arthalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Limb discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Sensation of heaviness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Coordination abnormal", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Disturbance in attention", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 16}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 16}]}, {"term": "Dysarthria", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Head discomfort", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 16}]}, {"term": "Paraesthesia oral", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}]}, {"term": "Speech disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Vision blurred", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 16}]}, {"term": "Erection increased", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Euphoric mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}]}, {"term": "Irritability", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Libido increased", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Mood altered", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Psychomotor retardation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Upper repiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dry skin", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Rash generalised", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Rash maculo-papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Eye pain", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Photophobia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Visual disturbance", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Gingival bleeding", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}]}, {"term": "Oral pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Blood pressure systolic increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Muscular discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Muscular stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Amnesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Coordination decreased", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Insomnia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Sensing disturbance", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Urine abnormality", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Skin irritation", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (9.1)", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Head of Clinical Research", "organization": "Bial - Portela & C\u00aa, S.A.", "email": "jose.rocha@bial.com", "phone": "+351 229 866 100"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077236", "term": "Topiramate"}, {"id": "C000416835", "term": "Eslicarbazepine acetate"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000061567", "term": "Voltage-Gated Sodium Channel Blockers"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M1711", "name": "Topiramate", "asFound": "Ad libitum", "relevance": "HIGH"}, {"id": "M262612", "name": "Eslicarbazepine acetate", "asFound": "Idiopathic Pulmonary Fibrosis", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}]}}, "hasResults": true}